BioSpace News Archive

Willow Biosciences Inc. is pleased to announce the results of its in vitro analysis and the first to be reported topical clinical study on cannabigerol (“CBG”).

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, January 26, 2022 , and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Orthofix Medical Inc today announced a partnership and investment agreement to jointly develop and co-market the innovative nView systems with Orthofix cervical spine and pediatric limb deformity correction procedural solutions.

Gamida Cell Ltd. announced that following receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration (FDA) yesterday, the company plans to initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant.

Yumanity Therapeutics today announced that, in response to its IND application submitted in December 2021, it was notified via email by the U.S. Food and Drug Administration (FDA) that the FDA has placed a partial clinical hold on multidose clinical trials of YTX-7739.

Vivos Therapeutics, Inc today announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST).

CytomX Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-developed by CytomX and Amgen.

Pathogenomix Inc. announced that the US Food and Drug Administration (FDA) has granted it a Breakthrough Device Designation for its Patho-Seq assay.

SiteOne will be responsible for research and early preclinical development activities; Vertex will be responsible for development, and commercialization.

Alterome Therapeutics, Inc. announced the closing of a $64M Series A financing.